{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"7.15","value":"3.93"},{"groupId":"OG001","lowerLimit":"1.58","upperLimit":"7.12","value":"3.90"},{"groupId":"OG002","lowerLimit":"1.53","upperLimit":"7.08","value":"3.89"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"24"}],"units":"Participants"}],"title":"DS-8201a, Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.58","upperLimit":"7.25","value":"4.00"},{"groupId":"OG001","lowerLimit":"0.58","upperLimit":"6.82","value":"4.00"},{"groupId":"OG002","lowerLimit":"0.68","upperLimit":"7.02","value":"4.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"11"}],"units":"Participants"}],"title":"DS-8201a, Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"7.15","value":"3.83"},{"groupId":"OG001","lowerLimit":"1.58","upperLimit":"7.08","value":"3.83"},{"groupId":"OG002","lowerLimit":"1.53","upperLimit":"7.08","value":"3.87"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"24"}],"units":"Participants"}],"title":"Total Anti-HER2 antibody, Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.53","upperLimit":"7.17","value":"3.98"},{"groupId":"OG001","lowerLimit":"0.57","upperLimit":"6.83","value":"4.00"},{"groupId":"OG002","lowerLimit":"0.53","upperLimit":"7.03","value":"3.75"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"11"}],"units":"Participants"}],"title":"Total Anti-HER2 antibody, Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.75","upperLimit":"7.25","value":"6.85"},{"groupId":"OG001","lowerLimit":"3.83","upperLimit":"141.73","value":"6.83"},{"groupId":"OG002","lowerLimit":"3.83","upperLimit":"7.08","value":"6.81"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"24"}],"units":"Participants"}],"title":"MAAA-1181a, Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.78","upperLimit":"7.25","value":"6.80"},{"groupId":"OG001","lowerLimit":"3.88","upperLimit":"7.10","value":"6.82"},{"groupId":"OG002","lowerLimit":"3.98","upperLimit":"7.07","value":"6.77"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"11"}],"units":"Participants"}],"title":"MAAA-1181a, Cycle 3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"24"}],"units":"Participants"}],"description":"Blood samples for DS-8201a pharmacokinetic (PK) analysis were obtained at the specified timepoints. The time to maximum serum concentration (Tmax) of DS-8201a was assessed. This serum PK parameter for DS-8201a, total anti-HER2 antibody, and MAAA-1181a were estimated in each participant using standard noncompartmental methods.","dispersionType":"Full Range","groups":[{"description":"Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive DS-8201a once every 3 weeks.","id":"OG000","title":"DS-8201a"},{"description":"Non-randomized participants with HER2 IHC 2+/ISH- advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every three weeks.","id":"OG001","title":"Exploratory: Naïve HER2 IHC 2+/ISH-, DS-8201a"},{"description":"Non-randomized participants with HER2 IHC 1+ advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every 3 weeks.","id":"OG002","title":"Exploratory: Naïve HER2 IHC 1+, DS-8201a"}],"paramType":"MEDIAN","populationDescription":"Pharmacokinetic parameters were assessed in the Pharmacokinetic Analysis Set.","reportingStatus":"POSTED","timeFrame":"Cycle 1 and 3, Day 1: predose, 4 hours (h), 7h postdose; Day 8, Day 15, and Day 22 postdose; Cycle 2, Day 1 and Day 22 postdose; Cycle 4, 6, and 8, Day 1 postdose (each cycle is 21 days)","title":"Pharmacokinetic Parameter of Time to Maximum Serum Concentration (Tmax) of DS-8201a, Total Anti-HER2 Antibody and MAAA-1181 Following Treatment With DS-8201a","type":"SECONDARY","unitOfMeasure":"hours"}